FDA Questions Genzyme Corporation Knee Pain Treatment Study

December 5, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON, Dec 5 (Reuters) - A study of Genzyme Corp's latest version of its injectable knee pain treatment may not be strong enough to support the therapy, U.S. regulatory reviewers said in an analysis released on Friday.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II

Food and Drug Administration (FDA)